银屑病的新型口服疗法：全面综述
New Oral Therapies for Psoriasis: A Comprehensive Review.
作者信息
Goldenberg Gary, Lanoue Julien, Dong Joanna
机构信息
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
出版信息
J Clin Aesthet Dermatol. 2016 Aug;9(8):25-8. Epub 2016 Aug 1.
Abstract
Conventional oral therapies for psoriasis, including methotrexate, cyclosporine, and acitretin, have generally unfavorable safety profiles and are not ideal for long-standing use. Thus, new oral therapies are necessary for patients with more moderate disease, patients who prefer oral treatments to injectable biologies, and patients who failed conventional therapies. The authors review here the clinical and safety evidence of phosphodiesterase 4 inhibitor, apremilast, janus kinase inhibitors, including tofacitinib, and fumarie acid esters as additional options in oral psoriasis therapy.
摘要
银屑病的传统口服疗法，包括甲氨蝶呤、环孢素和阿维A，总体安全性不佳，不适合长期使用。因此，对于病情较为中度的患者、比起注射用生物制剂更倾向口服治疗的患者以及传统疗法失败的患者而言，新型口服疗法很有必要。作者在此回顾磷酸二酯酶4抑制剂阿普斯特、包括托法替布在内的 Janus激酶抑制剂以及富马酸酯作为口服银屑病治疗额外选择的临床和安全性证据。
相似文献
1
New Oral Therapies for Psoriasis: A Comprehensive Review.银屑病的新型口服疗法：全面综述
J Clin Aesthet Dermatol. 2016 Aug;9(8):25-8. Epub 2016 Aug 1.
2
Review on Novel Oral Therapies for Psoriasis.银屑病新型口服疗法综述
J Clin Aesthet Dermatol. 2021 Dec;14(12):55-63.
3
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.新型银屑病和银屑病关节炎口服治疗药物。
Am J Clin Dermatol. 2016 Jun;17(3):191-200. doi: 10.1007/s40257-016-0179-3.
4
New and emerging oral therapies for psoriasis.银屑病的新型口服疗法
Drugs Context. 2024 Aug 1;13. doi: 10.7573/dic.2024-5-6. eCollection 2024.
5
Current and future oral systemic therapies for psoriasis.银屑病的当前及未来口服全身治疗方法。
Dermatol Clin. 2015 Jan;33(1):91-109. doi: 10.1016/j.det.2014.09.008.
6
Translating the 2020 AAD-NPF Guidelines of Care for the Management of Psoriasis With Systemic Nonbiologics to Clinical Practice.将 2020 年 AAD-NPF 系统用非生物制剂治疗银屑病的治疗指南转化为临床实践。
Cutis. 2021 Feb;107(2):99-103. doi: 10.12788/cutis.0177.
7
Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature.银屑病口服全身治疗的长期安全性：文献综述
Dermatol Ther (Heidelb). 2020 Aug;10(4):589-613. doi: 10.1007/s13555-020-00409-4. Epub 2020 Jun 11.
8
9
Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.阿普米拉斯与其他疗法联合用于治疗慢性斑块状银屑病：一项回顾性研究。
J Cutan Med Surg. 2016 Jul;20(4):313-6. doi: 10.1177/1203475416631328. Epub 2016 Feb 4.
10
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.银屑病关节炎和银屑病患者的定制治疗方案：已确立及新型生物制剂和小分子疗法综述
Rheumatol Int. 2016 May;36(5):603-12. doi: 10.1007/s00296-016-3436-0. Epub 2016 Feb 18.
引用本文的文献
1
Chinese Medicine for Psoriasis Vulgaris Based on Syndrome Pattern: A Network Pharmacological Study.基于证型的寻常型银屑病的中药网络药理学研究
Evid Based Complement Alternat Med. 2020 Apr 28;2020:5239854. doi: 10.1155/2020/5239854. eCollection 2020.
2
A Randomized Controlled Trial with a Medical Device Containing Sodium Hyaluronate and Nicotinic Acid to Increase the Efficacy of Ultraviolet Phototherapy in Psoriasis.一项使用含透明质酸钠和烟酸的医疗器械提高紫外线光疗治疗银屑病疗效的随机对照试验。
Dermatol Ther (Heidelb). 2020 Aug;10(4):651-662. doi: 10.1007/s13555-020-00385-9. Epub 2020 May 9.
3
Whether Fire-needle Therapy Benefits Plaque Psoriasis: A Multicenter, Randomized, and Controlled Trial.火针疗法是否有益于斑块状银屑病：一项多中心、随机、对照试验。
Chin J Integr Med. 2019 Apr;25(4):259-263. doi: 10.1007/s11655-018-2940-8. Epub 2019 Feb 27.
4
A clinical review of phototherapy for psoriasis.银屑病光疗的临床综述。
Lasers Med Sci. 2018 Jan;33(1):173-180. doi: 10.1007/s10103-017-2360-1. Epub 2017 Oct 24.
5
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.阿普米司特：用于银屑病和银屑病关节炎的治疗。
Drugs. 2017 Mar;77(4):459-472. doi: 10.1007/s40265-017-0709-1.
本文引用的文献
1
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).阿普米司特，一种口服磷酸二酯酶 4 抑制剂，治疗中重度斑块状银屑病患者的疗效和安全性：一项为期 52 周的 III 期随机对照试验（ESTEEM 2）。
Br J Dermatol. 2015 Dec;173(6):1387-99. doi: 10.1111/bjd.14164. Epub 2015 Nov 7.
2
Oral fumaric acid esters for psoriasis.用于治疗银屑病的口服富马酸酯类药物。
Cochrane Database Syst Rev. 2015 Aug 10;2015(8):CD010497. doi: 10.1002/14651858.CD010497.pub2.
3
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.托法替尼，一种口服 Janus 激酶抑制剂，用于治疗慢性斑块状银屑病：两项随机、安慰剂对照、III 期临床试验的结果。
Br J Dermatol. 2015 Oct;173(4):949-61. doi: 10.1111/bjd.14018.
4
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).阿普米司特，一种口服磷酸二酯酶 4（PDE4）抑制剂，用于治疗中重度斑块状银屑病患者：一项 III 期、随机、对照试验（评估阿普米司特治疗银屑病的疗效和安全性试验 [ESTEEM] 1）的结果。
J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049.
5
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.托法替尼对比依那西普或安慰剂治疗中重度慢性斑块型银屑病：一项 3 期随机非劣效性试验。
Lancet. 2015 Aug 8;386(9993):552-61. doi: 10.1016/S0140-6736(14)62113-9. Epub 2015 Jun 4.
6
The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).阿普米司特（一种口服磷酸二酯酶 4 抑制剂）对银屑病关节炎患者循环炎症生物标志物水平的药效学影响：来自 III 期、随机、安慰剂对照试验（PALACE 1）的亚研究结果。
J Immunol Res. 2015;2015:906349. doi: 10.1155/2015/906349. Epub 2015 Apr 20.
7
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.一项 2a 期随机、双盲、安慰剂对照、序贯剂量递增研究，旨在评估新型 Janus 激酶抑制剂 ASP015K 在中重度银屑病患者中的疗效和安全性。
Br J Dermatol. 2015 Sep;173(3):767-76. doi: 10.1111/bjd.13745. Epub 2015 Jun 19.
8
Acitretin in psoriasis: an evolving scenario.阿维A在银屑病中的应用：不断演变的情况。
Int J Dermatol. 2014 May;53(5):525-38. doi: 10.1111/ijd.12365. Epub 2014 Mar 6.
9
The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.托法替尼（一种 Janus 激酶抑制剂）在人体内的药代动力学、代谢和清除机制。
Drug Metab Dispos. 2014 Apr;42(4):759-73. doi: 10.1124/dmd.113.054940. Epub 2014 Jan 24.
10
Tofacitinib and other kinase inhibitors in the treatment of psoriasis.托法替布及其他激酶抑制剂在银屑病治疗中的应用
Actas Dermosifiliogr. 2013 May;104(4):304-10. doi: 10.1016/j.adengl.2013.03.002. Epub 2013 Apr 11.
Zotero 插件